The Latest Breaking News from Intellia rapeutics

The FDA is taking a cautious approach to gene editing clinical trials in the United States, forcing companies to go overseas for early data generation.

Three privately-held biotech companies could be next in line for making the jump to public markets.

Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

  Intellia Therapeutics (NASDAQ:NTLA) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Intellia Therapeutics will report an earnings per share (EPS) of $-1.10.

Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

 

Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:

Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis.